633fb99857c58.pdf
DOI:
Mavjud emas
S.K. Sevinch, O. Orun, P.M. Tiber, P.Chilka-Suzgun,S.G. Kuchukguzel. Anti-cancer activity of etodolac and its derivatives on prostate and colorectal cancer cell lines. Proceedings 2018, 2, 1573. DOI: 10.3390/proceedings2251573.
R.L. Dreiser. A comparison of the efficacy of etodolac SR and etodolac in patients with rheumatoid arthritis or osteoarthritis. Rheumatol. Int. 1993, 13(Suppl 2), 13-18. https://doi.org/10.1007/BF00290279.
B.N. Coskun, B. Yagiz, Y. Pehlivan, E. Dalkilic. Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review. Rheumatol. Int. 2019. https://doi.org/10.1007/s00296-019-04434-1.
British Pharmacopoeia, 2004.
K.P. Shah, K.Gumbhir-Shah, H.G. Brittain. Etodolac.Analitical profiles of drug substances and excipients 2002, 29, 105-147.
A.A. Gouda, M.I. Kotb El-Sayed, A.S. Amin, R. El-Sheikh. Spectrophotometric and spectrofluorometric methods for the determination of non-steroidal anti-inflammatory drugs: A review. Arabian J. Chem. -2013. -6. –P. 145-163.
Y. Jin, J. Zhao, L. Rhyman, P. Ramasami, Y. Shin, K.M. Jeong, J. Lee. Ultrasound-assisted chiral derivatization of etodolac with (1R)-(-)-menthyl chloroformate for the determination of etodolac enantiomers. Arabian J. Chem. -2016. -9. –P. 1962-1972.
CrysAlisPro. Ver. 1.171.33.40, UK: Oxford Diffraction, 2007.
G.M. Sheldrick, Acta Crystallogr. A 46 (1990) 467.
G.M. Sheldrick, SHELXS97, SHELXL97, Programs for Crystal Structures Solution and Refinement, University of Göttingen, Göttingen, Germany, 1997.
X.P. Siemens, Molecular Graphics Program. Version 5.03, Siemens Analytical X-Ray Instruments Inc., Madison (WI, USA), 1994.
Etodolac (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic Acid): A Potent Antiinflammatory Drug. Conformation and Absolute Configuration of Its Active Enantiomer. L.G. Humber, C.A. Demerson, P. Swaminathan, P.H. Bird. J. Med. Chem. -1986. -29. –P. 871-874.